Can You Get an Organ Transplant if You Smoke Weed?

Norman Smith had liver cancer, and his own oncologist recommended cannabis for the treatment. In February 2011 his hospital removed him from the transplant list after he tested positive for it.

He was told to complete six months of drug abuse counseling with random testing. He stopped using, his cancer came back during the wait, and he died in July 2012 without the transplant.

Nothing in federal transplant policy required any of that. Nothing prohibited it either, and that gap is the entire subject of this article.

The short answer

There is no national rule. Your transplant center decides, and the state its building stands in matters more than most patients ever learn.

Around twenty states now ban denying a transplant solely over medical cannabis. Everywhere else, a positive test can quietly end your candidacy.

Nobody is in charge of this question

People assume the national transplant network sets eligibility. It does not. The federal ethics guidance says plainly that transplant centers are encouraged to develop their own guidelines for transplant consideration, adding that evidence linking potentially injurious behaviors to transplant outcomes is inconclusive, and that a history of such behavior, once addressed, should not on its own disqualify anyone.

When a Maine patient went public after being delisted over medical cannabis, the network's own spokesman put it in one sentence: the decision to list or not is up to the transplant program, and there is no policy saying such a patient must be accepted or denied.

So the question has fifty answers, and they live in hospital policy documents most patients never see.

What the states have done about it

California moved first, after the Smith case. Its 2015 law says a hospital or physician shall not determine the ultimate recipient of an anatomical gift based solely upon a potential recipient's status as a qualified patient, with an exception where a doctor finds the use medically significant to the individual case.

Washington's version adds the operative caveat: medical use may not be the sole disqualifying factor unless it is shown that this use poses a significant risk of rejection or organ failure. Illinois goes further and declares authorized use the equivalent of any other physician-directed medication. Maine rewrote its rules after its own scandal. Arizona, Delaware and New Hampshire were among the early adopters, and by the start of 2025, when Kentucky's law took effect, the count stood at roughly 22 states.

Notice what every one of those laws shares: the word solely. A center can still weigh cannabis alongside everything else. What it cannot do, in those states, is turn a patient down on the test result alone.

What centers actually think

The published surveys show a profession split down the middle. A survey of 360 heart and lung transplant providers found 64.4 percent supported listing patients using legal medical cannabis, while only 27.5 percent supported listing recreational users, and about two thirds required a period of abstinence. A 2024 survey of heart transplant clinicians found answers diverging sharply by geography, with centers in legal states far more likely to even have a written cannabis policy, and the authors concluding that significant heterogeneity exists.

One university transplant program's own patient handout shows what the strict end looks like in practice, telling patients that many insurance companies require stopping cannabis before approval, and stating flatly that marijuana can cause fatal fungal infections after transplant.

That warning is well founded. It is the strongest genuine argument in the whole debate, and it deserves a fair hearing.

The unexamined day is a wasted opportunity. Reflect on what you did, what you learned, and how you can improve.

John Dewey

The real risks, honestly stated

Two clinical concerns survive scrutiny, and neither is about getting high. The first is fungus. Smoked cannabis can carry Aspergillus spores, and a transplant patient on immunosuppressants has had the defenses that normally shrug those spores off deliberately switched off. A CDC analysis of insurance claims found cannabis users were 3.5 times more likely to have a fungal infection than non-users. Fatal aspergillosis in transplant recipients who smoked cannabis exists in the case literature going back to the 1980s.

The second is a drug interaction. Cannabinoids inhibit the enzyme that clears tacrolimus, the backbone anti-rejection drug, and a published case documented a patient whose tacrolimus levels roughly tripled on high-dose CBD. Tacrolimus at excessive levels damages the kidneys, including a transplanted one.

Both risks are real but also manageable: the fungal risk attaches to smoking specifically, and the interaction is a monitoring problem, which is why disclosure to the team matters more than abstinence purity.

What the outcomes data says

Here is what centers rarely volunteer: when researchers compare transplant outcomes between cannabis users and non-users, the differences mostly fail to appear.

A kidney cohort of 1,225 recipients found isolated recreational use not associated with poorer patient or kidney allograft outcomes at one year. A registry study found cannabis dependence in the year before transplant not associated with death or graft failure in the year after. A liver cohort of 1,489 candidates found no mortality increase. A pooled analysis across nearly 56,000 kidney recipients found no significant association with graft failure or death overall.

The evidence base is cohort studies, not trials, and one meta-analysis flagged a possible signal on one narrow endpoint. But the direction is consistent, and it is not the direction the strictest policies assume.

What this means if you are on the path to a list

Three practical things follow from all of the above. Ask early which policy your center applies, because centers differ more than states do. Tell the team what you use, because the tacrolimus interaction is only dangerous when nobody is watching for it. And if a transplant is anywhere on your horizon, stop smoking specifically, whatever else you decide, because the fungal risk is the one argument on the restrictive side that outcome data does not soften.

If you are in a state without a protection law and get delisted over cannabis alone, know that the federal guidance quoted above is on your side in spirit, and that patient advocacy pushed roughly twenty state laws through in a decade. The Maine patient whose case built that state's law testified in 2017. The law passed.

The part a seed company can say

Most people reading this are not waiting for a transplant, but plenty live with someone who is, and that changes one practical thing about growing at home.

Immunosuppression in the house changes the calculus of growing, because a flowering room is a humid room full of plant matter, and plant matter carries mold spores. That is a manageable problem for a healthy grower and a genuinely bad idea in the home of someone whose immune system is being held down on purpose. If someone in your home is post-transplant or waiting, the grow belongs somewhere else, full stop.

For everyone else, mold resistance is an underrated selection criterion, and it is one breeders can actually influence. Dense buds in humid climates rot from the inside. Genetics with looser structure and proven resistance keep a harvest clean.

Apple Fritter is Animal Cookies crossed with Sour Apple, a balanced 50/50 at 30% THC, flowering in 65 to 70 days at 90 to 110 cm indoors, sweet apple pastry over cheese and diesel, relaxed and creative. Dos Si Dos Auto is the easier plant, a 65% indica autoflower at 23%, 70 to 75 days from seed at 80 to 110 cm, lemon meringue over sweet cookie, with heavy resin and a strong calm finish.

Four decades of breeding has taught us that a clean grow is mostly airflow, restraint on humidity, and genetics chosen for the room they will actually live in.

The short version

No national body decides whether cannabis disqualifies you from a transplant. Each center sets its own policy, federal ethics guidance leans against automatic disqualification, and roughly 22 states now prohibit denial based solely on medical cannabis use.

The two genuine clinical risks are fungal infection from smoked flower under immunosuppression and a documented interaction that can triple tacrolimus levels. Outcome studies across tens of thousands of recipients mostly find no penalty in survival or graft function for cannabis users.

Patients have died waiting after cannabis-only delistings, which is why the state laws exist. Ask your center's policy early, disclose what you use, and stop smoking if a transplant is in your future.

Barney's Farm has been developing premium cannabis genetics since the 1980s, with over 40 Cannabis Cup wins. Explore our full seed catalog and find strains bred for every climate and skill level.